| Abstract: | Objective To explore the efficacy of Xinmailong injection on septic cardiomyopathy. Methods A randomized controlled, single-blind study was conducted. 36 patients diagnosed with septic cardiomyopathy were randomly divided into control group （n = 19） and cardiomyopathy group （n = 17）. All patients in the 2 groups were given standardized treatment according to the 2018 International Guidelines for the Management of Sepsis and Septic Shock, and hemodynamic monitoring was performed by PICCO monitor during treatment. The experimental group was treated with Xinmailong injection on the basis of standard treatment, and the control group was injected with 0.9% sodium chloride injection at the same time. Peripheral venous blood was extracted from patients before treatment, 24 h, 72 h and 120 h after treatment, respectively, to detect troponin I and B brain natriuretic peptide, Doppler echocardiography was used to evaluate cardiac function, and hemodynamic blood related indexes showed by PICCO were compared.The experimental data were statistically analyzed by SPSS 19.0 statistical software. Results Compared with the control group, the levels of Cardiac Troponin I and brain natriuretic peptide B in experimental groups were significantly decreased. Left ventricular ejection fraction （LVEF）, tricuspid annular plane systolic excursion （TAPSE）, E/A increased, E peak deceleration time decreased; Stroke volume index （SVI） and cardiac function index （CFI） increased, and the difference was statistically significant （P < 0.05）. Conclusion Xinmailong injection can improve the cardiac function of patients with septic cardiomyopathy. |
